A multi‐center, retrospective study in 2022 assessed 233 tumor samples with historic HER2‐low and HER2‐negative scoring that were rescored using IHC and nonstaining assays and showed an 82.3% concordance between historic and regraded samples.21 This evidence concerns the gene ERBB2 and neoplasm.